TRDA vs. NLTX, STOK, LRMR, ALT, DNTH, KALV, OCS, ABUS, MRNS, and ANRO
Should you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Neoleukin Therapeutics (NLTX), Stoke Therapeutics (STOK), Larimar Therapeutics (LRMR), Altimmune (ALT), Dianthus Therapeutics (DNTH), KalVista Pharmaceuticals (KALV), Oculis (OCS), Arbutus Biopharma (ABUS), Marinus Pharmaceuticals (MRNS), and Alto Neuroscience (ANRO). These companies are all part of the "pharmaceutical preparations" industry.
Neoleukin Therapeutics (NASDAQ:NLTX) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.
Neoleukin Therapeutics received 39 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Entrada Therapeutics an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.
In the previous week, Entrada Therapeutics had 11 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 11 mentions for Entrada Therapeutics and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 1.16 beat Entrada Therapeutics' score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the news media.
Entrada Therapeutics has higher revenue and earnings than Neoleukin Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.
Neoleukin Therapeutics presently has a consensus price target of $30.00, suggesting a potential downside of 39.10%. Entrada Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 46.34%. Given Neoleukin Therapeutics' higher possible upside, analysts clearly believe Entrada Therapeutics is more favorable than Neoleukin Therapeutics.
Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.52, meaning that its share price is 152% less volatile than the S&P 500.
Neoleukin Therapeutics has a net margin of 0.00% compared to Neoleukin Therapeutics' net margin of -5.18%. Neoleukin Therapeutics' return on equity of -2.89% beat Entrada Therapeutics' return on equity.
52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Entrada Therapeutics beats Neoleukin Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Entrada Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Entrada Therapeutics Competitors List
Related Companies and Tools